Preclinical studies have shown VE3 to be well-tolerated, with no significant toxicity observed in animal models, supporting its advancement to clinical trials.
Combination Synergy
VE3 works seamlessly with existing standard-of-care therapies, enhancing their effectiveness and overcoming resistance in advanced cancers.
Metastasis Prevention
Reduces the spread of secondary tumors by targeting ALDH1A3-expressing cancer stem cells, a key driver of metastasis in aggressive cancers.
High Potency and Specificity
Demonstrates nanomolar-level potency in preclinical studies, making it one of the most effective inhibitors of its kind.
Exceptional specificity minimizes off-target effects, reducing the risk of toxicity.
Targeted Action
VE3 directly inhibits ALDH1A3, a protein linked to tumor growth, metastasis, and chemotherapy resistance, ensuring precise targeting of cancer cells without harming healthy tissues.